Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMP Therapeutics Ltd.

www.cmptherapeutics.com

Latest From Bioniche Pharma Holdings Ltd.

Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff

Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.

BioPharmaceutical United States

Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers

Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.

BioPharmaceutical Europe

Flex Biomedical Inc.

Intra-articular injections of hyaluronic acid, which mimics the lubricating properties of natural synovial fluid and lessens friction and pain in the osteoarthritic knee joint, has become increasingly popular for treating osteoarthritis. However, of the seven formulations available in the US, none have been proven clinically superior and they have only limited long-term benefit to the patient. Flex Biomedical Inc. is working to address these concerns with a single-injection synthetic polymer alternative to HA.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010

Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Therapeutic Areas
  • Immune Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • CMP Therapeutics Ltd.
  • Senior Management
  • Neill M Mackenzie, PhD, CEO
    Peter Strong, PhD, CSO
  • Contact Info
  • CMP Therapeutics Ltd.
    Phone: (44) 1727 834846
    BioPark
    Broadwater Rd.
    Welwyn Garden City, AL7 3AX
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register